Pure Global AI
NCT06223906Recruiting

A Registry Study of Biomarkers in Heart Valve Disease

Beijing Institute of Heart, Lung and Blood Vessel DiseasesClinicalTrials.gov
Verified
Study focus
Disease/Condition
Cardiovascular Diseases
Study type
Observational
Sponsor & location
Primary sponsor
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
Jan 01, 2016
End date
Jan 01, 2030
Enrollment
200000 participants
Primary outcome

All-cause death

Summary

Valvular Heart Disease, impacting 2.5% of the population, is predominantly observed in the
 elderly and is on the rise. The primary conditions within this category are Aortic Stenosis
 and Mitral Regurgitation. These conditions are linked to considerable morbidity and
 mortality, presenting a formidable challenge in optimizing treatment strategies.
 Pathophysiology of Valvular Heart Disease remains poorly known. The aim of the present study
 is to identify biomarkers involved in this disease using multi-omics approaches

ICD-10 classifications
Cardiovascular disease, unspecifiedHypertensive heart diseaseOther ill-defined heart diseasesHeart disease, unspecifiedObservation for other suspected cardiovascular diseases
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06223906
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06223906 through Pure Global AI's free database. This phase not specified trial is sponsored by Beijing Institute of Heart, Lung and Blood Vessel Diseases and is currently Recruiting. The study focuses on Cardiovascular Diseases. Target enrollment is 200000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.